Mylonib 5mg Tablet (Ruxolitinib) — Price in Pakistan Brand: Mylonib Generic: Ruxolitinib 5mg Manufacturer: Pharmasol (Pvt) Ltd. Pack Sizes: 10s, 20s, 60s Dosage Form: Tablet Category: Oncology / Haematology Important Notice: Mylonib 5mg Tablet is a prescription oncology medicine used in the treatment of serious blood disorders. It must be prescribed by a qualified haematologist or oncologist and used under clinical supervision. The information on this page is for reference purposes only and does not constitute medical advice. What Is Mylonib 5mg Tablet? Mylonib 5mg Tablet is an oral targeted therapy manufactured by Pharmasol (Pvt) Ltd., a DRAP-registered Pakistani pharmaceutical company. Each tablet contains Ruxolitinib phosphate 5mg, a selective Janus Kinase (JAK) inhibitor that belongs to the class of myeloproliferative neoplasm treatments. Ruxolitinib is the active ingredient in Mylonib and is internationally recognized as a first-line treatment for myelofibrosis and polycythaemia vera. It is also used in the management of graft-versus-host disease (GVHD). As a locally manufactured alternative to imported brands such as Jakavi, Mylonib offers patients in Pakistan access to this critical therapy at a more accessible price point. At OncoLink Pharmacy, we stock authentic Mylonib 5mg Tablets from Pharmasol, making this essential haematology medicine available to patients and healthcare providers across Pakistan with reliable nationwide delivery. Mylonib 5mg Uses and Indications Mylonib 5mg Tablet (Ruxolitinib) is approved and indicated for the following conditions: Myelofibrosis (MF): Mylonib is indicated for the treatment of intermediate-2 or high-risk primary myelofibrosis, post-polycythaemia vera myelofibrosis, and post-essential thrombocythaemia myelofibrosis. It works by reducing abnormal spleen enlargement (splenomegaly) and alleviating debilitating disease-related symptoms, such as night sweats, fatigue, bone pain, and itching. Polycythaemia Vera (PV): Mylonib is prescribed for adult patients with polycythaemia vera who are resistant to or intolerant of hydroxycarbamide (hydroxyurea). It helps control haematocrit levels, reduces spleen size, and improves quality of life. Acute Graft-Versus-Host Disease (aGVHD): In patients aged 12 years and above, Mylonib is used in combination with corticosteroids to treat steroid-refractory acute GVHD following allogeneic stem cell transplantation. Chronic Graft-Versus-Host Disease (cGVHD): Mylonib is used as a second-line treatment for chronic GVHD in patients who have not responded to one or two prior lines of systemic therapy. How Mylonib (Ruxolitinib) Works Mylonib belongs to the class of JAK1/JAK2 inhibitors, targeted medicines that block specific proteins responsible for driving abnormal cell growth in certain blood disorders. In myelofibrosis and polycythaemia vera, mutations in the JAK2 gene (particularly the JAK2V617F mutation, present in approximately 50% of myelofibrosis patients) lead to uncontrolled activation of the JAK-STAT signalling pathway. This drives overproduction of blood cells, inflammatory cytokines, bone marrow scarring, and organ enlargement. Ruxolitinib selectively inhibits JAK1 and JAK2, suppressing this abnormal signalling, reducing cytokine levels, shrinking the spleen, and improving symptoms. In GVHD, JAK inhibition suppresses alloreactive T-cell activation and inflammatory cytokine production (including IL-6 and IFN-γ), reducing immune-mediated tissue damage. Mylonib 5mg Dosage and Administration Mylonib tablets are taken orally, with or without food. Dosing is individualised based on the indication, the patient’s platelet count, kidney and liver function, and any concurrent medications. Starting doses for adults are as follows: Myelofibrosis — dose based on platelet count at initiation: Platelet Count Starting Dose Above 200 × 10⁹/L 20mg twice daily 100–200 × 10⁹/L 15mg twice daily 50–99 × 10⁹/L 10mg twice daily Below 50 × 10⁹/L Not recommended Polycythaemia Vera: 10mg twice daily (if platelets above 100 × 10⁹/L). Acute GVHD: 5mg twice daily in combination with corticosteroids. Chronic GVHD: 10mg twice daily. Dose adjustments are required in patients with moderate to severe kidney impairment, moderate hepatic impairment, or those taking strong CYP3A4 inhibitor medicines. Mylonib should never be stopped abruptly — dose tapering over 1–2 weeks is recommended to avoid a withdrawal rebound syndrome. Mylonib 5mg Side Effects All patients on Mylonib should be closely monitored by their haematologist throughout treatment. The most commonly reported side effects include: Very Common (affecting 1 in 10 or more patients): Anaemia — dose-dependent and may require transfusion or dose reduction Thrombocytopenia (low platelet count) — dose-limiting Neutropenia (low white blood cell count) Bruising and easy bleeding Dizziness and headache Diarrhoea and nausea Fatigue Elevated liver enzymes (usually mild) Increased cholesterol levels Serious Side Effects (seek immediate medical attention): Serious infections, including tuberculosis reactivation, herpes zoster (shingles), pneumonia, and urinary tract infections Progressive multifocal leukoencephalopathy (PML) — a rare but potentially fatal brain infection Non-melanoma skin cancers with long-term use Hepatitis B reactivation Acute pancreatitis (rare) Important Precautions and Warnings Infections: Ruxolitinib is an immunosuppressant. Patients must be screened for latent tuberculosis and hepatitis B before starting Mylonib. Report any signs of infection (fever, cough, night sweats) to your doctor immediately. Blood Count Monitoring: Anaemia and thrombocytopenia are common and dose-dependent. Regular blood tests are mandatory. Abrupt Discontinuation: Never stop Mylonib suddenly. Abrupt withdrawal can trigger rapid spleen enlargement, fever, and a dangerous inflammatory rebound. Always taper under medical guidance. Skin Cancer: Long-term use is associated with an increased risk of basal cell and squamous cell carcinoma. Annual skin examinations are recommended. Pregnancy and Breastfeeding: Ruxolitinib may cause harm to an unborn baby. Effective contraception must be used during treatment and for at least 2 weeks after the final dose. Breastfeeding should be discontinued during treatment. Drug Interactions: Mylonib is metabolised by CYP3A4. Concurrent use of strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, clarithromycin) increases ruxolitinib levels significantly, requiring dose reduction. Strong inducers (e.g., rifampicin, phenytoin, carbamazepine) reduce efficacy and should be avoided. Mylonib 5mg Price in Pakistan Mylonib 5mg Tablet is manufactured locally by Pharmasol (Pvt) Ltd. and is available in pack sizes of 10, 20, and 60 tablets. As a DRAP-registered product, its MRP is set under regulatory guidelines. For the current price of Mylonib 5mg in Pakistan, please contact OncoLink Pharmacy: WhatsApp / Call: +92 327 6170609 Email: info@oncolinkpharmacy.com Location: Lahore, Punjab, Pakistan Nationwide Delivery: Available to all major cities Why Buy Mylonib 5mg from OncoLink Pharmacy? OncoLink Pharmacy is Pakistan’s dedicated oncology and haematology pharmacy based in Lahore. We understand that medicines for blood disorders like myelofibrosis are time-sensitive and clinically critical. Authentic Stock: We source Mylonib 5mg Tablets directly from Pharmasol (Pvt) Ltd., a DRAP-licensed manufacturer. Counterfeit or substandard medicines are never stocked. Haematology Expertise: Our pharmacy specializes in oncology, haematology, and rheumatology; we are not a general pharmacy. Our team understands the clinical context of specialist medicines like Ruxolitinib. Competitive Pricing: Mylonib offers Pakistani patients access to Ruxolitinib therapy at a more affordable price than imported equivalents. OncoLink Pharmacy ensures transparent, competitive pricing. Nationwide Delivery: We deliver to Lahore, Karachi, Islamabad, Rawalpindi, Faisalabad, Multan, Peshawar, Quetta, and all cities across Pakistan. Secure packaging is maintained for all specialty medicines. Frequently Asked Questions What is Mylonib 5mg used for? Mylonib 5mg (Ruxolitinib) is used to treat myelofibrosis, polycythaemia vera, and graft-versus-host disease (GVHD). It works by blocking JAK1 and JAK2 enzymes that drive abnormal blood cell production and inflammatory signaling in these conditions. Who manufactures Mylonib 5mg in Pakistan? Mylonib 5mg is manufactured by Pharmasol (Pvt) Ltd., a DRAP-registered pharmaceutical company headquartered in Lahore, Pakistan. What is the price of Mylonib 5mg in Pakistan? The MRP for Mylonib 5mg is set by DRAP. For the current confirmed price, please contact OncoLink Pharmacy at +92 327 6170609. Is Mylonib the same as Jakavi? Both Mylonib and Jakavi contain Ruxolitinib as their active ingredient and are approved for the same indications. Jakavi is an internationally imported brand, while Mylonib is manufactured locally by Pharmasol. Your specialist can advise on the appropriate option for your treatment. Can I stop Mylonib suddenly? No. Abruptly stopping Mylonib can cause a serious rebound reaction including rapid spleen enlargement and a dangerous inflammatory response. Always taper the dose gradually under your doctor’s guidance. Does Mylonib 5mg require a prescription? Mylonib 5mg is a specialist haematology medicine and should always be used under the supervision of a qualified haematologist or oncologist with a valid prescription. OncoLink Pharmacy recommends consultation with a registered specialist before use.